This case illustrates that due to individual variations, even standard drug dosages may induce neuroleptic malignant syndrome (NMS). Notably, NMS lacks specific laboratory findings, and its diagnosis must rely on clinical symptoms to avoid delays in early identification and treatment.
Liu et al. (Wed,) studied this question.